Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events

Summary Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIRM’s pipeline expansion and strategic acquisitions have delayed profitability to 2028, but management raised FY 2026 sales guidance to $680–$700 million. Strong commercial traction from LIVMARLI and bile acid products drove Q2 revenue above expectations, but operating losses widened due to R&D and integration costs. With FY 2028 revenue estimates at $1.03 billion and EPS at $1.85, MIRM is positioned as a leading rare liver disease company; dips into the mid-$80s may offer entry points. Mohammed Haneefa Nizamudeen/iStock via Getty Images Since my first BUY report in May 2025, when Mirum Pharmaceuticals ( MIRM ) was trading at $43.69 a share, the ticker is up 115%. The bulk of that appreciation occurred in two brief phases—August This article was written by Sean Daly 2.3K Followers Follow Sean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has also written extensively on real estate and economic development, exploring issues as diverse as Chinese urbanization, CMI multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds. Global strategy and private equity background. Equity Approach: long/short, event-driven, with a focus on small cap biotech and the emerging markets. Analyst’s Disclosure: I/we have a beneficial long position in the shares of MIRM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.